Status:
COMPLETED
Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325
Lead Sponsor:
AstraZeneca
Conditions:
Anxiety
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA recept...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg
- Clinically normal physical findings, medical history and laboratory values.
Exclusion
- Clinically significant illness or clinical relevant trauma within 2 weeks before the study start.
- Intake of another investigational drug or participation in a clinical study the past 12 weeks.
- Previous participation in a PET study within the past 12 months. Suffer from claustrophobia and would be unable to undergo MRI (magnetic resonance imaging) or PET scanning.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00681720
Start Date
February 1 2008
End Date
July 1 2008
Last Update
August 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden